Idoven, Epoch Biodesign, Mojia Biotech
Idoven Raises $19.8M in Funding
Idoven, a Madrid, Spain-based health tech company advancing early detection and precision medicine for cardiovascular diseases, raised $19.8m in funding.
The funding consists of a $12.9m Series A round co-led by global software investor Insight Partners and Northzone with participation from Wayra. The round is also supplemented by $6.9m in grant and equity funding awarded by the European Innovation Council (EIC) Accelerator. A prominent list of angel investors joined the round, including Ron Vianu, Founder and CEO of Covera Health; Brad Fluegel, Former SVP, Chief Healthcare Commercial Officer and Strategy Officer at Walgreens; and Vlad Lata, Founder and CEO of Avi Medical, among others. The round was also joined by existing angels, including Iker Casillas, captain of Spain’s World Cup-winning football team and UNDP ambassador, and former senior executives from Amazon and Apple, Diego Piacentini and Sebastian Gunningham. This round follows a $2m seed round raised 12 months ago from business angels, Wayra and the Accel Starter program.
The company intends to use the funds to further develop its AI platform to identify arrhythmias and cardiac abnormalities, as well as accelerate hiring to advance early diagnosis and precision medicine of cardiovascular diseases.
Led by CEO Dr. Marina Manuel Breysse, Idoven is a health technology company for cardiovascular diseases. Its AI-powered platform, Willem, delivers substantial improvements to the speed, consistency and accuracy of electrocardiogram (ECG) interpretation and prediction. The proprietary AI algorithms, which work with existing ECG devices, are also being applied to develop disease biomarkers towards patient identification, risk stratification and prognosis, as well as drug cardiac safety monitoring.
Idoven Raises $19.8M in Funding - FinSMEs
Idoven, a Madrid, Spain-based health tech company advancing early detection and precision medicine for cardiovascular diseases, raised $19.8m in funding
Scintil Photonics Raises €13.5M in Second Financing Round
Scintil Photonics, a Grenoble, France-based supplier of silicon photonic integrated circuits with monolithically integrated lasers and optical amplifiers, raised €13.5M in Second funding.
The round was led by Robert Bosch Venture Capital with participation from Supernova Invest, Innovacom and Bpifrance.
The company intends to use the funds to accelerate CMOS-based industrialization and global commercialization of its III-V Augmented Silicon Photonic ICs for optical interconnects.
Led by CEO Sylvie Menezo, Scintil Photonics develops and markets Photonic Integrated Circuits (PICs): integrated laser arrays, multiples of 800 Gbit/sec transmitters and receivers, tunable transmitters and receivers, as well as optical I/O for near chip and chip-chip communication). Its circuits are fabricated on a proprietary III/V-Augmented Silicon Photonics technology manufactured in a multi-customer silicon foundry. For accelerated adoption, the company also delivers the control electronics and reference package implementations.
Scintil Photonics Raises €13.5M in Second Financing Round
Scintil Photonics, a Grenoble, France-based supplier of silicon photonic integrated circuits with monolithically integrated lasers and optical amplifiers, raised €13.5M in Second funding
Epoch Biodesign Raises $11M in Seed Funding
Epoch Biodesign, a London, UK-based Total BioDesignTM Company, raised $11M in seed funding.
The round was led by Lowercarbon Capital, with participation from BoxGroup, Amadeus Capital Partners, MCJ Collective, Zero Carbon capital, VOYAGERS Climate-Tech Fund, The Venture Collective, and more.
The company intends to use the funds for the expansion of its protein design platform, construction of new R&D facilities and further development and scale up of their first solution.
Led by CEO Jacob Nathan, Epoch Biodesign is a company developing natural solutions for unnatural problems with the mission to scale and industrialize biology for a healthy planet. With a combination of proprietary computational and experimental tools, Epoch is advancing biorecycling: a tuneable enzymatic process to transform plastic waste into everyday chemicals.
Epoch Biodesign Raises $11M in Seed Funding
Epoch Biodesign, a London, UK-based Total BioDesignTM Company, raised $11M in seed funding
PicnicHealth Closes $60M Series C Financing
PicnicHealth, a San Francisco, CA-based patient-centered health technology company, closed a $60m Series C financing.
The round, which brought the total amount raised to date to more than $100m, was led by new investor B Capital Group with participation from existing investors Felicis Ventures and Amplify Partners. In conjunction with the funding, Adam Seabrook, Partner at B Capital Group, joined the PicnicHealth board of directors.
The company intends to use the funds to grow its portfolio of patient-centered real-world data cohorts across 30 new indications in complex, chronic, or rare conditions, introduce new capabilities to bring this depth and completeness to aid clinical trial sponsors in linking trial data with longitudinal real-world outcomes, and to streamline and speed the patient experience of gaining access to up-to-date medical records.
Founded in 2014 by Noga Leviner and Troy Astorino, PicnicHealth is a healthcare technology company that partners directly with patients to build deep real-world datasets. The company leverages machine learning, combined with human curation, to port complete medical records into an online application. The platform gives patients access to and control over their medical records and, with their consent, the opportunity to contribute this valuable data to further scientific research. The company partners with dozens of the world’s largest biopharma companies and academic research institutions.
PicnicHealth Closes $60M Series C Financing
PicnicHealth, a San Francisco, CA-based patient-centered health technology company, closed a $60m Series C financing
Mojia Biotech Completes $80M Series B Financing
Mojia Biotech, a Shanghai, China-based bio-manufacturing company, raised $80M in Series B funding.
The round was led by Temasek with participation from LYZZ Capital, Sento Investment, Bits x Bites, Asia Green Fund.
The company intends to use the funds to commercialize its Viridimin™ brand of animal-feed additives, scale up manufacturing capacity for Aliphane™ series of bio-based materials, advance its product pipeline and expand its global R&D capabilities.
Led by Ansen Chiew, Mojia Biotech is a product-focused bio-manufacturing company dedicated to the production of food ingredients and chemical materials using renewable carbon sources and green processes. In the past few years, the company has developed innovative pathways to produce Viridimin™ brand of Vitamin B5. The second product that Mojia Biotech aims to bring to the market is Aliphane™ series of biopolymer products, which is extremely versatile and has great potential in coating and adhesive applications.
Mojia Biotech Completes $80M Series B Financing - FinSMEs
Mojia Biotech, a Shanghai, China-based bio-manufacturing company, raised $80M in Series B funding
EQT buys SPT Labtech for £650 million to speed up life science research
UK-based genomics laboratory automation startup, SPT Labtech, has been acquired by EQT from Battery Ventures for £650 million. The automation of research, miniaturisation trends, and broader adoption of multi-omics will support SPT’s core liquid handling business for years to come.
Founded in 1997 and owned by Battery Ventures since 2018, the Melbourn-based company manufactures and designs automated liquid handling, sample preparation, storage instruments, and corresponding consumables and support services for life science research. SPT helps researchers save time through automation and enables labs to research chronic illnesses, provide treatments, or find cures for previously untreatable conditions.
EQT will further support the company in new product innovation, expansion into existing and new geographies and end-markets such as catering to the in-vitro diagnostics market, and doubling down on APAC and M&A to further strengthen SPT’s market position.
EQT buys SPT Labtech for £650 million to speed up life science research - Tech.eu
EQT will support SPT Labtech’s next phase of growth by focusing on continued product innovation and growing the business in new and existing geographies
True Wealth Ventures Closes $35M Fund II
True Wealth Ventures, an Austin, TX-based seed-stage venture capital firm invests in companies improving human and environmental health with at least one woman on the founding or executive team, closed its second fund, at $35M.
More than 75% of capital raised by True Wealth Ventures across Fund I & Fund II is backed by 80% female LPs. True Wealth’s total AUM is now about $60m. The seed-stage VC firm focuses on maximizing the number of women in its funds to invest in women-led companies.
Led by Founding General Partner Sara Brand and General Partner Kerry Rupp, True Wealth Ventures invests exclusively in women-led, seed-stage companies that improve human and environmental health, with Brand or Rupp assuming board seats. Fund II will invest across the spectrum of software, hardware and consumer packaged goods startups. First checks typically range between $500,000 and $1 million. True Wealth Ventures LPs often co-invest an additional 50% on top of the Fund’s investment, with total rounds most often ranging up to $3.5 to $4 million.
True Wealth already has made three investments from Fund II since its first close in May 2021:
Aeromutable, a San Diego-based startup that applies aerospace technology to the trucking industry, enhancing vehicle efficiency and safety; De Oro Devices, a company headquartered in California, which makes mobility devices to assist people with mobility disorders to walk safely and confidently; and, Flourish, a startup headquartered in Austin, Texas, which educates women how to build sustainable habits in nutrition, hydration, sleep, stress, relationships and movement. The firm intends to invest in 15 companies from Fund II.
